ITB-MED AB
559017-9429ActiveDeveloping novel antibody therapy to eliminate post-transplant immunosuppression needs.
Oversikt
- 10–19
- Ansatte
- 50–100mill SEK
- Omsetning
- 2015
- Grunnlagt
Beskrivelse
ITB-MED is a specialized biotechnology company focused on transforming organ transplantation outcomes. The organization is developing TCD601 (siplizumab), a proprietary antagonistic CD2-directed monoclonal antibody. This novel therapy aims to achieve transplantation tolerance, potentially freeing pa...
Tagger
Nøkkelord
Bedriftsinformasjon
- Bransje
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- MVA-nummer
- SE559017942901
Beslutningstakere
Ingen beslutningstakere funnet ennå
Lignende bedrifter
20 lignende bedrifter i FunnelfeedriCoat Medical AB
1–4 ansatteDeveloping drugs to improve organ transplantation outcomes globally.
iCoat Medical Operations AB
Developing drugs to improve organ transplantation outcomes globally.
GLYCOREX TRANSPLANTATION AB (PUBL)
10–19 ansatteDevelops technology to remove blood antibodies for transplants and disease.
Circio AB
Developing circular RNA expression systems for enhanced gene therapies.
Sangair AB
3 ansatteDeveloping revolutionary blood treatment technology to combat severe sepsis infections.
Utforsk mer
Spørsmål om ITB-MED AB
Vil du se Funnelfeedr i aksjon?
Book en gratis demo og oppdag hvordan Funnelfeedr hjelper deg med å finne og konvertere dine ideelle kunder.
Book en demo